Japan & GSK plc
3 shared events · Importance 3 · Last updated Jun 30, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Japan: Regulators in Japan are considering bepirovirsen, which could expand the drug's market reach and provide a new treatment option for patients in the country.
GSK plc: As a developer and funder of bepirovirsen, GSK plc stands to benefit significantly from the drug's potential approval and market success, enhancing its reputation and financial outlook in the pharmaceutical industry.
May 28, 2026 · 8 articles
Business
Japan: Japan's Nikkei 225 index saw substantial gains, supported by tech-related shares and positive economic indicators like manufacturing PMI and export data, reflecting a healthy market performance.
GSK plc: GSK plc>>> agreed to acquire GSK plc>>> for $10.6 billion, marking its largest deal in years and expanding its presence in cancer drug development.
May 20, 2026 · 72 articles
Business
Japan: Nikkei fell sharply; yen at 40-year low.
GSK plc: Soared 39% after GSK agreed to buy it for $10.6 billion.
Apr 20, 2026 · 344 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Japan and GSK plc interact across events, view sentiment trends, and discover connected entities.
Open Dashboard